Essential3 is the first positive Phase 3 program in essential tremor; ulixacaltamide has received FDA Breakthrough Therapy Designation, with data selected for plenary presentation at AAN 2026 Praxis ...
Acquired License to Phase 3 Lasofoxifene Development Program of Novel Selective Estrogen Receptor Modulator (SERM), a Potential Multi-Billion Dollar Opportunity as Treatment Option for Breast Cancer ...
Initiation of Phase 1 proof-of-mechanism study of EQ504 planned for mid-2026, with data expected approximately six months thereafterCash and cash ...
Detailed price information for Ovid Therapeutics Inc (OVID-Q) from The Globe and Mail including charting and trades.
Lipocine Inc. (NASDAQ: LPCN), a biopharmaceutical company leveraging its proprietary technology platform to augment therapeutics through effective oral delivery, today announced financial results for ...
The biggest stories of the day delivered to your inbox.
Nektar Therapeutics is basking in the honeyed glow of long-term phase 2 data for its immune asset rezpegaldesleukin in atopic dermatitis, where the candidate successfully reduced the size and ...
WASHINGTON (AP) — The United States said Wednesday that it is moving into the next phase of a Gaza ceasefire plan that involves disarming Hamas, rebuilding the war-ravaged territory and establishing ...
A new technical paper titled “Hybrid tungsten oxyselenide/graphene electrodes for near-lossless 2D semiconductor phase modulators” was published by researchers at Nanyang Technological University, ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results